文献速递乳腺癌

转移性乳腺癌化疗后维持内分泌治疗的应用

Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer.
PubMed 文献 · Eur J Cancer · 2016-11-12

本文综述了转移性乳腺癌化疗后引入内分泌治疗是否获益的证据,发现相关试验规模小且方案与当前不同,序贯内分泌治疗可能适度改善至进展时间但无总生存获益,在因毒性停药且无进展时使用低毒性内分泌治疗以延缓复发是合理方法。

要点

  • 化疗后序贯内分泌治疗可能适度改善至进展时间,但无总生存获益。
  • 证据来自四项小规模试验,化疗方案和内分泌治疗均与当前不同。
  • 因毒性停化疗且无进展时,使用低毒性内分泌治疗延缓复发是合理方法。

核心结论

  • 在转移性乳腺癌化疗因毒性中止且无疾病进展时,使用相对低毒的内分泌治疗以延缓复发是合理方法。
  • 化疗后序贯内分泌治疗可能适度改善至进展时间,但无总生存获益。

研究设计与样本

  • 文献综述,纳入四项探讨转移性乳腺癌化疗后内分泌治疗是否获益的试验。
  • 同时检索了同期化疗联合内分泌治疗及化疗持续至疾病进展等替代方案的证据。

主要发现

  • 支持转移性乳腺癌化疗后使用内分泌治疗的证据有限,且已完成的试验规模小。
  • 这些试验开展的时期,化疗方案和内分泌治疗均与当前使用的不同。
  • 尽管存在上述局限,化疗后序贯内分泌治疗可能适度改善至进展时间,但无总生存获益。
  • 替代方案包括化疗持续至疾病进展,尤其考虑口服生物利用氟尿嘧啶类等相对低毒药物。

临床怎么用

  • 转移性乳腺癌化疗因毒性中止且无进展时,作者认为使用相对低毒的内分泌治疗以延缓复发是合理方法。
  • 替代方案为化疗持续至疾病进展,尤其考虑口服生物利用氟尿嘧啶类等相对低毒药物。

局限性

  • 支持转移性乳腺癌化疗后使用内分泌治疗的证据有限。
  • 已完成的试验规模小。
  • 试验开展的时期化疗方案和内分泌治疗均与当前使用的不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For women with oestrogen receptor+ metastatic breast cancer (MBC), the options for systemic treatment include endocrine therapy (ET) and chemotherapy. For women whose disease is also HER2+, anti-HER2 therapies are also routinely used either with chemotherapy or less commonly with ET. Where chemotherapy is used as initial therapy, treatment is often discontinued due to cumulative toxicity in the absence of disease progression. In this setting, there is the option of introducing ET with the aim of prolonging response and delaying relapse. METHODS: Literature review revealed four trials addressing the question of whether there is a benefit from introducing ET following chemotherapy for MBC. We also sought evidence for alternative approaches, including concurrent chemotherapy and ET and continuing chemotherapy until disease progression. RESULTS: The evidence for the use of ET after chemotherapy in MBC is limited, and the trials done were small. Furthermore, they were performed at a time when both the chemotherapy regimens and ET were different from those used currently. Despite these limitations, there is probably a modest improvement in time to progression for the sequential use of ET after chemotherapy but with no overall survival benefit. An alternative approach, particularly considering agents with relatively low toxicity, such as orally bioavailable fluoropyrimidines, is to continue chemotherapy until disease progression. CONCLUSION: Where chemotherapy for MBC is discontinued due to toxicity, in the absence of progression, the use of ET, with its relatively low toxicity, is a reasonable approach with the aim of delaying relapse.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sutherland S, Miles D, Makris A, et al. Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer. Eur J Cancer. 2016. PMID: 27847222. doi:10.1016/j.ejca.2016.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。